The regulation of PD-1/PD-L1 pathway and autoimmune diseases

被引:0
|
作者
Okazaki, T [1 ]
Iwai, Y [1 ]
Nishimura, H [1 ]
Honjo, T [1 ]
机构
[1] Kyoto Univ, Dept Med Chem, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan
关键词
autoimmune disease; dilated cardiomyopathy; autoantibody;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PD-1 is an immuno-inhibitory receptor which belongs to the immunoglobulin superfamily and expressed on activated T, B and myeloid cells. Engagement of the PD-1 receptor with its membrane bound ligand (PD-LI) of the B7 family inhibits the proliferation of anti-CD3 stimulated T cells as well as anti-IgM stimulated B cells (Freeman et al. 2000 and our unpublished observation). Disruption of PD-1 gene in C57BL/6 mice caused typical lupus-like glomerulonephritis and destructive arthritis as they age (Nishimura et al. 1999) while in BALB/c mice caused autoantibody mediated dilated cardiomyopathy with severely impaired contraction and sudden death by congestive heart failure. Affected hearts showed diffuse deposition of IgG on the surface of cardiomyocytes. All of the affected PD-1(-/-) mice exhibited high-titered circulating IgG autoantibodies reactive to a 33-kDa protein expressed specifically on the surface of cardiomyocytes (Nishimura et al. 2001). These results indicate that PD-1 may be an important factor contributing to the prevention of autoimmune diseases.
引用
收藏
页码:211 / 214
页数:4
相关论文
共 50 条
  • [1] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [2] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
    Zhang, Ke
    Kong, Xiangyi
    Li, Yuan
    Wang, Zhongzhao
    Zhang, Lin
    Xuan, Lixue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] A snapshot of the PD-1/PD-L1 pathway
    Ghosh, Chinmoy
    Luong, Gary
    Sun, Yue
    JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
  • [4] Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
    Ding, Lei
    Lu, Shengdi
    Li, Yanli
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (02) : 651 - 663
  • [5] The PD-1/PD-L1 Pathway in Human Pathology
    Saresella, M.
    Rainone, V.
    Al-Daghri, N. M.
    Clerici, M.
    Trabattoni, D.
    CURRENT MOLECULAR MEDICINE, 2012, 12 (03) : 259 - 267
  • [6] PD-1/PD-L1 Pathway in Breast Cancer
    Schuetz, Florian
    Stefanovic, Stefan
    Mayer, Luisa
    von Au, Alexandra
    Domschke, Christoph
    Sohn, Christof
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 294 - 297
  • [7] Expression of PD-1, PD-L1 and PD-L2 within liver of autoimmune liver diseases
    Mataki, Norikazu
    Kikuchi, Kentaro
    Kawai, Toshihim
    Okada, Yoshikiyo
    Kurihara, Chic
    Watanabe, Chikako
    Kohmoto, Shunsuke
    Hokari, Ryota
    Kawaguchi, Atsushi
    Nagao, Shigeaki
    Kondo, Toshiro
    Itoh, Kazuro
    Miyakawa, Hiroshi
    Miura, Soichiro
    GASTROENTEROLOGY, 2006, 130 (04) : A280 - A280
  • [8] Regulation of autoimmune diabetes in NOD mice:: Critical role for the PD-1:PD-L1 costimulatory pathway.
    Ansari, MJI
    Salama, AD
    Auchincloss, H
    Sayegh, MH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 345A - 345A
  • [9] Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
    Liang, SC
    Latchman, YE
    Buhlmann, JE
    Tomczak, MF
    Horwitz, BH
    Freeman, GJ
    Sharpe, AH
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (10) : 2706 - 2716
  • [10] The PD-1/PD-Ls pathway and autoimmune diseases
    Dai, Suya
    Jia, Ru
    Zhang, Xiao
    Fang, Qiwen
    Huang, Lijuan
    CELLULAR IMMUNOLOGY, 2014, 290 (01) : 72 - 79